Development of a nasal formulation containing ketorolac tromethamine and metoclopramide hydrochloride

S.T.P. Pharma Sciences

Volumn 12, Issue 1, 2002, Pages 39-44

  Sheth, P ^a   Zia, H ^a   Needham, T ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Ketorolac tromethamine; Metoclopramide hydrochloride; Nasal delivery

Indexed keywords

ANTIEMETIC AGENT; KETOROLAC TROMETAMOL; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ARTICLE; CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SELF ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MIGRAINE; NAUSEA; NONHUMAN; PAIN; PATIENT COMPLIANCE; POSTOPERATIVE PAIN; RABBIT; VOMITING;

EID: 0036146839     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Migraine
2. Ketorolac tromethamine in cancer pain
3. The use of ketorolac in the management of postoperative pain
4. The effects of ventilation of ketorolac in comparison with morphine
5. Ketorolac: A review of it's pharmacodynamic and pharmacokinetic properties and therapeutic potential
6. Development and evaluation of nasal formulations of ketorolac
7. Migraine and drug absorption
8. Gastrointestinal actions of metoclopramide in the intestine. An experimental study
9. Inhibition of apomorphine of the metoclopramide-induced catalepsy and increase in striatal homivanillic acid content
10. Clinical pharmacokinetics of metoclopramide
11. Bioadhesive dosage form for nasal administration
12. Effect of concentration and volume on nasal bioavailability and biological response to desmopressin
13. Bioahesive and formulation parameters affecting nasal absorption
14. Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography
15. Pharmacokinetics comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers
16. Nasal absorption of metoclopramide administered to man
17. Bioavailability of intranasal metoclopramide